ERTAFAST is a brand of Ertapenem, a penem antimicrobial. It is structurally very similar to meropenem in that it possesses a 1-β-methyl group. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. Ertapenem is indicated in adult and pediatric patients (3 months of age and older) for the treatment of the cautious to serious infections. Ertapenem has a longer half-life than the older carbapenems, hence allowing for once-daily administration. ERTAFAST provides convenience of outpatient parenteral antibiotic therapy because of once a day dosing. In a study ERTAFAST showed a success rate of 93.7%. Eertapenem showed least MIC and higher killing rate than Pipracillin/Tazobactam.
|Product||Active Ingredient(s)||Strength||Features||Dosage Form|
• Effective against MDR ESBLs
• Longer Half-Life
• Once a Day Convenient dosing
• High Clinical Cure Rate